Praxis Precision Medicines (PRAX) has reported a robust cash and cash equivalents balance of $926 million as of December 31, 2025. This strong financial position is expected to provide the company with an extended operational runway. The company has not provided further details on specific expenditures or revenue drivers contributing to this balance in the provided information.

Key Takeaways

• Praxis Precision Medicines ended 2025 with $926 million in cash and cash equivalents.
• This balance is anticipated to extend the company's financial runway.

The company's next quarterly earnings report will provide further insight into its financial performance and future projections.

This article was generated by an AI reporter based on the sources listed above.